A. Kann

发表

HYP-FAST trial study protocol: a phase II, single-center, open-label RCT comparing the effect of early time-restricted feeding on blood pressure control versus standard of care in individuals with primary hypertension

N. Kaegi-Braun, J. Oller, J. Souza, 2021, Principles and Practice of Clinical Research Journal.

Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries

A. Sasse, P. Salman, D. Herchenhorn, 2021, JCO global oncology.

716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy

T. Powles, H. Nishiyama, L. Makaroff, 2021, Annals of Oncology.

Exploring the role of novel agents in the treatment of renal cell carcinoma.

A. Buzaid, J. Aguilar-Ponce, J. G. De la Garza, 2008, Cancer treatment reviews.

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)

M. Maia, S. Gillessen, J. Zarbá, 2021, JCO global oncology.

"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".

O. Smaletz, G. Carvalhal, A. Sasse, 2022, Clinical genitourinary cancer.

The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer

L. Klotz, S. Rangarajan, A. Avezum, 2022, JACC. CardioOncology.

Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

R. Barroso-Sousa, G. de Castro, K. T. Souza, 2014, Medical Oncology.

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

B. Rini, V. Master, R. Uzzo, 2022, The Lancet.

LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

R. Uzzo, J. Karam, M. Zibelman, 2022, Annals of Oncology.